![]() |
![]() |
|||||||||||||||||||||||||||||||||||||||||||||||
Understanding heart attack Coronary death rate
Annual death rate from coronary heart disease
There has been in the last 3 years numerous changes and additions to the healthful website as JK realized the extent of corruption worked by pharma on the evidence base. Major revision in causes of heart disease. Two Changes in content coming up
For confirmation from journal articles on primary role of infective agent enter into http://scholar.google.com/ terms such as bacteria + atherosclerosis or go to http://healthfully.org/rl/id8.html and id9 for collection of articles For confirmation of cholesterol myth enter into http://scholar.google.com/ or http://www.amazon.com/ cholesterol myth, or go to http://healthfully.org/rl/id5.html for collection of journal articles.
The article below was done in 2009, before JK discovered the extent of the corruption worked by pharma. Much of what has been stated here was based upon a reliance of pharma’s opinion leaders. The recommended section of this website has a far better analysis—see http://healthfully.org/rc/ |
|||||||||||||||||||||||||||||||||||||||||||||||
![]() |
|
![]() |
![]() |
![]() |
Enter supporting content here Those who have a financial interest in the outcome manipulate the results, Major study finds that all 37 journal articles positive effects over stated; the average was 32%. Statins cause erectile dysfunction, cognitive imparement, and cancer. Lipitor (2011) lifetime sales $131
billion, tops all drugs. Plavix at
$60 billion is second.
STATINS CANCER Link 52% short term LA Times, Health section, Vytorin, the
combination drug (simvastatin (better known by its commercial name Zocor) and ezetimibe--known as Zetia) prescribed to lower
cholesterol, sustained another blow today, when the author of a major clinical trial announced that the medication had failed
to drive down hospitalization and death due to heart failure in patients with narrowing of the aortic valve. In the process,
researchers in Today's findings
suggested something more ominous: the incidence of cancer -- and of dying of cancer -- was significantly higher in the patients
taking Vytorin. Altogether, 67 patients on placebo developed cancer during the trial.
Among subjects on Vytorin, 102 developed cancers of various kinds.* This
is the second adverse press—the first being in March 08, when the ENHANCE trial found that Vytorin fared no better than
a placebo at reducing plaque buildup on the walls of patients' arteries.* * Comments by jk Simvastatin (Zocor) is off patent. Thus in a scramble for profits a combination drug (on patent) was introduced. Direct to consumer market cost $155 in 07—mainly TV ads. * The pressing issue is that since the development of Statins, the very first animal studies in the 60s it has been known that Statins increase the incidents of cancer. However, nearly all studies done thereafter have not included cancer. *
Several studies have failed to find a reduction in the build of plaque, even thought the statins including Zocor, reduce
EXTENDED RELEASE NIACIN IS A SAFER, AND A MORE EFFECTIVE WAY TO LOWER MI RISK! |